摘要
目的检测细胞周期蛋白Cyclin D1和凋亡抑制因子Survivin在乳腺癌中的表达,探讨其与乳腺癌的关系。方法采用免疫组化法检测40例乳腺癌组织、40例乳腺纤维腺瘤组织以及20例正常乳腺组织中Cyclin D1和Survivin的表达,并分析其临床病理意义。结果Cyclin D1和Survivin在乳腺癌组织中的阳性表达率分别为72.5%(29/40)和65.0%(26/40),在乳腺纤维腺瘤中的阳性表达率分别为27.5%(11/40)和25.0%(10/40),而在正常乳腺组织中无表达,在乳腺癌中的表达明显高于乳腺良性肿瘤及正常乳腺组织(P<0.01);Cyclin D1和Survivin的阳性表达与乳腺癌的病期、有无淋巴结转移密切相关(P<0.05),而与肿瘤大小无关(P>0.05);Cyclin D1的阳性表达和Survivin的阳性表达呈正相关。结论Cyclin D1和Survivin在乳腺良、恶性肿瘤及乳腺正常组织中的表达有明显的差异;其表达与乳腺癌的病期及淋巴结转移有关;Cyclin D1和Survivin的表达有相关性。
Objective To detect the expression of Cyclin D1 and Survivin in carcinoma of the breast, to approach the relation of them and carcinoma of the breast. Methods Elivision immunohistochem ical techhnique was used to assess the expressions of Cyclin D1 and Survivin in 40 cases of carcinoma of the breast ,40 cases of fibroadenoma of the breast and 20 cases of nomal breast tissues, to analyze clinical meaning. Results The positive rates of Cyclin D1 and Survivin in carcinoma of the breast are 72.5% (29/40)and 65% (26/40), the positive rates of Cyclin D1 and Survivin in fibroadenoma of the breast are 27.5% (11/40)和25% (20/40),but no expression in nomal breast tissues; the positive rates of Cyclin D1 and Survivin in carcinoma of the breast are highter than those in fibroadenoma of the breast and nomal breast tissues(P 〈 0.01 ) ; the positive expressions of Cyclin D1 and Survivin in carcinoma of the breast are concerned with stage and transfer of lymph node( P 〈0. 05 ), but no correlation with size of tumor (P 〉 0.05 ) ; the positive expressions of Cyelin D1 and Survivin in carcinoma of the breast offer direct correlation. Conclusion the expression of Cyclin D1 and Survivin have apparent difference in benign tumor of the breast, malignant tumor of the breast and nomal breast tissues; the expression are concerned with with stage and transfer of lymph node ;the detection of Cyclin D1 and Survivin in carcinoma of the breast can offer determinate studying found for its stage,prognosis assessment and biologic treat.
出处
《社区医学杂志》
2010年第5期1-3,共3页
Journal Of Community Medicine